APO Research
Talk to an analyst

APO RESEARCH · REPORT

Orphan Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Orphan Drugs Market Outlook and Growth Opportunities 2026

29 December 2025195 pages

Choose your research edition.

Industry ResearchOrphan Drugs Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Orphan Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Orphan Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Orphan Drugs Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Orphan Drugs Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Orphan Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Orphan Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Orphan Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Orphan Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Orphan Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Orphan Drugs market include AstraZeneca, AbbVie, Amgen, Bristol-Myers Squibb, Biogen, Vertex Pharmaceuticals, Pfizer, Eli Lilly and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Orphan Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Orphan Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Orphan Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Orphan Drugs market.

Orphan Drugs Segment by Company

AstraZeneca

AbbVie

Amgen

Bristol-Myers Squibb

Biogen

Vertex Pharmaceuticals

Pfizer

Eli Lilly

Roche

Novartis

Johnson & Johnson

Sanofi

Takeda

Orphan Drugs Segment by Type

Metabolic Disorders

Pulmonary

Endocrinology

Neurology

Cardio-vascular

Hematology

Oncology

Others

Orphan Drugs Segment by Application

Adult

Teenager

Baby and Child

Other

Orphan Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Orphan Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Orphan Drugs key companies, revenue, market share, and recent developments.

3. To split the Orphan Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Orphan Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Orphan Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Orphan Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Orphan Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Orphan Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Orphan Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Orphan Drugs industry.

Chapter 3: Detailed analysis of Orphan Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Orphan Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Orphan Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Orphan Drugs Industry Trends Table 2. Orphan Drugs Industry Drivers Table 3. Orphan Drugs Industry Opportunities and Challenges Table 4. Orphan Drugs Industry Restraints Table 5. Global Orphan Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Orphan Drugs Revenue Share by Company (2021-2026) Table 7. Global Orphan Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Orphan Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Orphan Drugs Company, Product Type & Application Table 10. Global Orphan Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Orphan Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Metabolic Disorders Table 15. Significant Companies of Pulmonary Table 16. Significant Companies of Endocrinology Table 17. Significant Companies of Neurology Table 18. Significant Companies of Cardio-vascular Table 19. Significant Companies of Hematology Table 20. Significant Companies of Oncology Table 21. Significant Companies of Others Table 22. Global Orphan Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 23. Global Orphan Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 24. Global Orphan Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 25. Global Orphan Drugs Sales Value Share by Type (2021-2026) Table 26. Global Orphan Drugs Sales Value Share by Type (2027-2032) Table 27. Significant Companies of Adult Table 28. Significant Companies of Teenager Table 29. Significant Companies of Baby and Child Table 30. Significant Companies of Other Table 31. Global Orphan Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Orphan Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 33. Global Orphan Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 34. Global Orphan Drugs Sales Value Share by Application (2021-2026) Table 35. Global Orphan Drugs Sales Value Share by Application (2027-2032) Table 36. Global Orphan Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Orphan Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 38. Global Orphan Drugs Sales Value Share by Region (2021-2026) Table 39. Global Orphan Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 40. Global Orphan Drugs Sales Value Share by Region (2027-2032) Table 41. Global Orphan Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 42. Global Orphan Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 43. Global Orphan Drugs Sales Value Market Share by Country (2021-2026) Table 44. Global Orphan Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 45. Global Orphan Drugs Sales Value Market Share by Country (2027-2032) Table 46. AstraZeneca Company Information Table 47. AstraZeneca Business Overview Table 48. AstraZeneca Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. AstraZeneca Orphan Drugs Product Portfolio Table 50. AstraZeneca Recent Development Table 51. AbbVie Company Information Table 52. AbbVie Business Overview Table 53. AbbVie Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. AbbVie Orphan Drugs Product Portfolio Table 55. AbbVie Recent Development Table 56. Amgen Company Information Table 57. Amgen Business Overview Table 58. Amgen Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Amgen Orphan Drugs Product Portfolio Table 60. Amgen Recent Development Table 61. Bristol-Myers Squibb Company Information Table 62. Bristol-Myers Squibb Business Overview Table 63. Bristol-Myers Squibb Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Bristol-Myers Squibb Orphan Drugs Product Portfolio Table 65. Bristol-Myers Squibb Recent Development Table 66. Biogen Company Information Table 67. Biogen Business Overview Table 68. Biogen Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Biogen Orphan Drugs Product Portfolio Table 70. Biogen Recent Development Table 71. Vertex Pharmaceuticals Company Information Table 72. Vertex Pharmaceuticals Business Overview Table 73. Vertex Pharmaceuticals Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Vertex Pharmaceuticals Orphan Drugs Product Portfolio Table 75. Vertex Pharmaceuticals Recent Development Table 76. Pfizer Company Information Table 77. Pfizer Business Overview Table 78. Pfizer Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Pfizer Orphan Drugs Product Portfolio Table 80. Pfizer Recent Development Table 81. Eli Lilly Company Information Table 82. Eli Lilly Business Overview Table 83. Eli Lilly Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Eli Lilly Orphan Drugs Product Portfolio Table 85. Eli Lilly Recent Development Table 86. Roche Company Information Table 87. Roche Business Overview Table 88. Roche Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Roche Orphan Drugs Product Portfolio Table 90. Roche Recent Development Table 91. Novartis Company Information Table 92. Novartis Business Overview Table 93. Novartis Orphan Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Novartis Orphan Drugs Product Portfolio Table 95. Novartis Recent Development Table 96. Johnson & Johnson Company Information Table 97. Johnson & Johnson Business Overview Table 98. Johnson & Johnson Orphan Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Johnson & Johnson Orphan Drugs Product Portfolio Table 100. Johnson & Johnson Recent Development Table 101. Sanofi Company Information Table 102. Sanofi Business Overview Table 103. Sanofi Orphan Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Sanofi Orphan Drugs Product Portfolio Table 105. Sanofi Recent Development Table 106. Takeda Company Information Table 107. Takeda Business Overview Table 108. Takeda Orphan Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Takeda Orphan Drugs Product Portfolio Table 110. Takeda Recent Development Table 111. Research Programs/Design for This Report Table 112. Authors List of This Report Table 113. Secondary Sources Table 114. Primary Sources List of Figures Figure 1. Orphan Drugs Product Image Figure 2. Global Orphan Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Orphan Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Orphan Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Metabolic Disorders Image Figure 8. Pulmonary Image Figure 9. Endocrinology Image Figure 10. Neurology Image Figure 11. Cardio-vascular Image Figure 12. Hematology Image Figure 13. Oncology Image Figure 14. Others Image Figure 15. Global Orphan Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Orphan Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Orphan Drugs Sales Value Share by Type (2021-2032) Figure 18. Adult Image Figure 19. Teenager Image Figure 20. Baby and Child Image Figure 21. Other Image Figure 22. Global Orphan Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Orphan Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Orphan Drugs Sales Value Share by Application (2021-2032) Figure 25. Global Orphan Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 26. Global Orphan Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 27. North America Orphan Drugs Sales Value (2021-2032) & (US$ Million) Figure 28. North America Orphan Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Europe Orphan Drugs Sales Value (2021-2032) & (US$ Million) Figure 30. Europe Orphan Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Asia-Pacific Orphan Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. Asia-Pacific Orphan Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. South America Orphan Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. South America Orphan Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Middle East & Africa Orphan Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Middle East & Africa Orphan Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. USA Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. USA Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. USA Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Canada Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Canada Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Canada Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Mexico Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Mexico Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Mexico Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Germany Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Germany Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Germany Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. France Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. France Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. France Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. U.K. Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. U.K. Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. U.K. Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Italy Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Italy Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Italy Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Spain Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Spain Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Spain Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Russia Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Russia Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Russia Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Netherlands Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Netherlands Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Netherlands Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Nordic Countries Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Nordic Countries Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Nordic Countries Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. China Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. China Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. China Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. Japan Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. Japan Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. Japan Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. South Korea Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. South Korea Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. South Korea Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. India Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. India Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. India Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Australia Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Australia Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Australia Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Southeast Asia Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Southeast Asia Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Southeast Asia Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Brazil Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Brazil Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Brazil Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Argentina Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Argentina Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Argentina Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Chile Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Chile Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Chile Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Colombia Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Colombia Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Colombia Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Peru Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Peru Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Peru Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Saudi Arabia Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Saudi Arabia Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Israel Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Israel Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Israel Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. UAE Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. UAE Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. UAE Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Turkey Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Turkey Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Turkey Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Iran Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Iran Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Iran Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Egypt Orphan Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Egypt Orphan Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Egypt Orphan Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Years Considered Figure 122. Research Process Figure 123. Key Executives Interviewed

Scope & coverage.

Types
  • Metabolic Disorders
  • Pulmonary
  • Endocrinology
  • Neurology
  • Cardio-vascular
  • Hematology
  • Oncology
  • Others
Applications
  • Adult
  • Teenager
  • Baby and Child
  • Other
Companies covered
  • AstraZeneca
  • AbbVie
  • Amgen
  • Bristol-Myers Squibb
  • Biogen
  • Vertex Pharmaceuticals
  • Pfizer
  • Eli Lilly
  • Roche
  • Novartis
  • Johnson & Johnson
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Orphan Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Orphan Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Orphan Drugs Market Dynamics
  1. 2.1 Orphan Drugs Industry Trends
  2. 2.2 Orphan Drugs Industry Drivers
  3. 2.3 Orphan Drugs Industry Opportunities and Challenges
  4. 2.4 Orphan Drugs Industry Restraints
3 Orphan Drugs Market by Company
  1. 3.1 Global Orphan Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Orphan Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Orphan Drugs Company Ranking (2024-2026)
  4. 3.4 Global Orphan Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Orphan Drugs Company Product Type and Application
  6. 3.6 Global Orphan Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Orphan Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Orphan Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Orphan Drugs Market by Type
  1. 4.1 Orphan Drugs Type Introduction
  2. 4.1.1 Metabolic Disorders
  3. 4.1.2 Pulmonary
  4. 4.1.3 Endocrinology
  5. 4.1.4 Neurology
  6. 4.1.5 Cardio-vascular
  7. 4.1.6 Hematology
  8. 4.1.7 Oncology
  9. 4.1.8 Others
  10. 4.2 Global Orphan Drugs Sales Value by Type
  11. 4.2.1 Global Orphan Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Orphan Drugs Sales Value by Type (2021-2032)
  13. 4.2.3 Global Orphan Drugs Sales Value Share by Type (2021-2032)
5 Orphan Drugs Market by Application
  1. 5.1 Orphan Drugs Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Teenager
  4. 5.1.3 Baby and Child
  5. 5.1.4 Other
  6. 5.2 Global Orphan Drugs Sales Value by Application
  7. 5.2.1 Global Orphan Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Orphan Drugs Sales Value by Application (2021-2032)
  9. 5.2.3 Global Orphan Drugs Sales Value Share by Application (2021-2032)
6 Orphan Drugs Regional Value Analysis
  1. 6.1 Global Orphan Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Orphan Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Orphan Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Orphan Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Orphan Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Orphan Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Orphan Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Orphan Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Orphan Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Orphan Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Orphan Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Orphan Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Orphan Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Orphan Drugs Sales Value Share by Country, 2025 VS 2032
7 Orphan Drugs Country-level Value Analysis
  1. 7.1 Global Orphan Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Orphan Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Orphan Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Orphan Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Orphan Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Orphan Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Orphan Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Orphan Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Orphan Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Orphan Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Orphan Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Orphan Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Orphan Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Orphan Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Orphan Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Orphan Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Orphan Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Orphan Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Orphan Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Orphan Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Orphan Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Orphan Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Orphan Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Orphan Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Orphan Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Orphan Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Orphan Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Orphan Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Orphan Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Orphan Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Orphan Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Orphan Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Orphan Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Orphan Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Orphan Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AstraZeneca
  2. 8.1.1 AstraZeneca Company Information
  3. 8.1.2 AstraZeneca Business Overview
  4. 8.1.3 AstraZeneca Orphan Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AstraZeneca Orphan Drugs Product Portfolio
  6. 8.1.5 AstraZeneca Recent Developments
  7. 8.2 AbbVie
  8. 8.2.1 AbbVie Company Information
  9. 8.2.2 AbbVie Business Overview
  10. 8.2.3 AbbVie Orphan Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 AbbVie Orphan Drugs Product Portfolio
  12. 8.2.5 AbbVie Recent Developments
  13. 8.3 Amgen
  14. 8.3.1 Amgen Company Information
  15. 8.3.2 Amgen Business Overview
  16. 8.3.3 Amgen Orphan Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Amgen Orphan Drugs Product Portfolio
  18. 8.3.5 Amgen Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Orphan Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Orphan Drugs Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Biogen
  26. 8.5.1 Biogen Company Information
  27. 8.5.2 Biogen Business Overview
  28. 8.5.3 Biogen Orphan Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Biogen Orphan Drugs Product Portfolio
  30. 8.5.5 Biogen Recent Developments
  31. 8.6 Vertex Pharmaceuticals
  32. 8.6.1 Vertex Pharmaceuticals Company Information
  33. 8.6.2 Vertex Pharmaceuticals Business Overview
  34. 8.6.3 Vertex Pharmaceuticals Orphan Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Vertex Pharmaceuticals Orphan Drugs Product Portfolio
  36. 8.6.5 Vertex Pharmaceuticals Recent Developments
  37. 8.7 Pfizer
  38. 8.7.1 Pfizer Company Information
  39. 8.7.2 Pfizer Business Overview
  40. 8.7.3 Pfizer Orphan Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pfizer Orphan Drugs Product Portfolio
  42. 8.7.5 Pfizer Recent Developments
  43. 8.8 Eli Lilly
  44. 8.8.1 Eli Lilly Company Information
  45. 8.8.2 Eli Lilly Business Overview
  46. 8.8.3 Eli Lilly Orphan Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Eli Lilly Orphan Drugs Product Portfolio
  48. 8.8.5 Eli Lilly Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Orphan Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Orphan Drugs Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Orphan Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Orphan Drugs Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 Johnson & Johnson
  62. 8.11.1 Johnson & Johnson Company Information
  63. 8.11.2 Johnson & Johnson Business Overview
  64. 8.11.3 Johnson & Johnson Orphan Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Johnson & Johnson Orphan Drugs Product Portfolio
  66. 8.11.5 Johnson & Johnson Recent Developments
  67. 8.12 Sanofi
  68. 8.12.1 Sanofi Company Information
  69. 8.12.2 Sanofi Business Overview
  70. 8.12.3 Sanofi Orphan Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Sanofi Orphan Drugs Product Portfolio
  72. 8.12.5 Sanofi Recent Developments
  73. 8.13 Takeda
  74. 8.13.1 Takeda Company Information
  75. 8.13.2 Takeda Business Overview
  76. 8.13.3 Takeda Orphan Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Takeda Orphan Drugs Product Portfolio
  78. 8.13.5 Takeda Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst